MBX Biosciences (MBX) Return on Capital Employed (2024 - 2026)

MBX Biosciences (MBX) has 3 years of Return on Capital Employed data on file, last reported at 24.43% in Q1 2026.

• For the quarter ending Q1 2026, Return on Capital Employed rose 856.0% year-over-year to 24.43%; the trailing twelve-month figure through Mar 2026 stood at 24.43% (up 856.0% YoY), and the FY2025 full-year result was 31.49%, up 976.0% from the prior year.
• Return on Capital Employed improved to 24.43% in Q1 2026, from 26.0% in the prior quarter.
• In the past five years, Return on Capital Employed ranged from a high of 24.43% in Q1 2026 to a low of 38.14% in Q2 2025.
• A 3-year average of 29.54% and a median of 27.96% in 2025 frame the typical range for Return on Capital Employed.
• Across the five-year window, Return on Capital Employed fell 21 bps in 2025 and jumped 856 bps in 2026, its largest moves.
• Tracing MBX's Return on Capital Employed over 3 years: stood at 25.79% in 2024, then retreated by 1 bps to 26.0% in 2025, then climbed by 6 bps to 24.43% in 2026.
• Business Quant data shows MBX's Return on Capital Employed at 24.43% in Q1 2026, 26.0% in Q4 2025, and 29.92% in Q3 2025.